TY - JOUR
T1 - Anti-inflammatory effect of rosuvastatin in patients with HIV infection
T2 - An FDG-PET pilot study
AU - Boczar, Kevin E.
AU - Faller, Elliot
AU - Zeng, Wanzhen
AU - Wang, Jerry
AU - Small, Gary R.
AU - Corrales-Medina, Vicente F.
AU - deKemp, Robert A.
AU - Ward, Natalie C.
AU - Beanlands, Rob S.B.
AU - MacPherson, Paul
AU - Dwivedi, Girish
PY - 2022/12
Y1 - 2022/12
N2 - Aims: This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin. Methods and results: Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV− control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16− and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBRmax), spleen (SUVmax) and thoracic aortic (TBRmax) in the statin-treated group compared to the control group (bone marrow: − 10.3 ± 16.9% versus 5.0 ± 18.9%, p = .0262; spleen: − 9.8 ± 20.3% versus 11.3 ± 28.8%, p = .0497; thoracic aorta: − 19.1 ± 24.2% versus 4.3 ± 15.4%, p = .003). Conclusions: HIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.
AB - Aims: This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin. Methods and results: Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV− control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16− and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBRmax), spleen (SUVmax) and thoracic aortic (TBRmax) in the statin-treated group compared to the control group (bone marrow: − 10.3 ± 16.9% versus 5.0 ± 18.9%, p = .0262; spleen: − 9.8 ± 20.3% versus 11.3 ± 28.8%, p = .0497; thoracic aorta: − 19.1 ± 24.2% versus 4.3 ± 15.4%, p = .003). Conclusions: HIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.
KW - Atherosclerosis
KW - Cardiovascular risk
KW - FDG-PET/CT
KW - HIV
KW - Inflammation
KW - Rosuvastatin
UR - http://www.scopus.com/inward/record.url?scp=85120629309&partnerID=8YFLogxK
U2 - 10.1007/s12350-021-02830-4
DO - 10.1007/s12350-021-02830-4
M3 - Article
C2 - 34820771
AN - SCOPUS:85120629309
SN - 1071-3581
VL - 29
SP - 3057
EP - 3068
JO - Journal of Nuclear Cardiology
JF - Journal of Nuclear Cardiology
IS - 6
ER -
